Semaglutide has become the dominant force in prescription weight management, while AOD-9604 circulates in the background as a peptide fragment with a narrower metabolic profile. The comparison between the two is not straightforward. One is a GLP-1 receptor agonist with a large clinical trial record; the other is a modified fragment of human growth hormone with a much thinner evidence base. For people targeting stubborn fat, the question is less about which compound is "better" and more about what each one actually does inside the body.
Semaglutide works primarily by mimicking GLP-1, a hormone that slows gastric emptying and reduces appetite. AOD-9604, by contrast, was designed to retain the lipolytic region of growth hormone without its effects on blood sugar or cell growth. That distinction matters. A 2021 review in Nature Reviews Endocrinology noted that GLP-1 agonists produce weight loss mainly through reduced energy intake, not direct fat oxidation. AOD-9604, if it works at all, would act on fat cells more directly.
The regulatory paths are equally different. Semaglutide is FDA-approved for chronic weight management under the brand Wegovy. AOD-9604 is not approved for any medical use in the United States, and most vendors sell it as a research chemical. That gap shapes how practitioners talk about the two compounds.
What the clinical data show for semaglutide
The semaglutide evidence base is large and consistent. In the STEP 1 trial, published in 2021, participants taking 2.4 mg of semaglutide weekly lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% for placebo. A 2022 analysis in The Lancet Diabetes & Endocrinology confirmed that most of that loss came from fat mass, with visceral fat reduced more than subcutaneous fat. That is relevant for people asking about stubborn fat, since visceral fat is the metabolically active depot linked to cardiovascular risk.
But semaglutide does not selectively target any single fat region. The drug reduces overall energy intake, and fat loss follows a pattern determined by genetics and hormones. Some users report that belly fat is the last to go. That is normal physiology, not a failure of the drug. A 2023 review in Obesity Reviews noted that GLP-1 agonists do not change the regional distribution of fat loss beyond what would be expected from total weight reduction.
- Average weight loss in STEP trials: 14-17% from baseline
- Fat mass accounts for roughly 70-80% of total weight lost
- Visceral fat reduction is proportional to overall loss, not site-specific
- Appetite suppression is the main mechanism, not direct lipolysis
For practitioners, semaglutide is the reference standard when a patient needs substantial, sustained weight loss. The prescribing conversation is straightforward: dose titration, side effect management, and long-term adherence. The drug is expensive, and supply has been inconsistent, but the clinical pathway is clear.
What AOD-9604 claims to do
AOD-9604 is a 16-amino acid fragment of the C-terminus of human growth hormone. It was developed in the 1990s by metabolic researchers looking for a lipolytic agent that would not raise blood glucose or promote cell proliferation. Early animal studies suggested it could reduce body fat in obese rodents without affecting appetite. A 2003 paper in Endocrinology reported that AOD-9604 increased fat oxidation in isolated rat adipocytes.
Human data are much thinner. A 2006 phase 2b trial in obese adults found no significant difference in weight loss between AOD-9604 and placebo after 12 weeks. The company developing the drug, Metabolic Pharmaceuticals, later abandoned it for obesity. Since then, AOD-9604 has lived on in the gray market, sold as a peptide for "stubborn fat" and often paired with other research chemicals.
The mechanism, if any, is thought to involve beta-3 adrenergic receptor activation in fat cells, similar to the way growth hormone stimulates lipolysis. But the evidence for that in humans is weak. A 2019 review in Frontiers in Endocrinology concluded that AOD-9604's lipolytic effects in humans are "unproven and likely modest at best."
- No FDA approval for any indication
- Sold as a research chemical, not for human use
- Human trial data from 2006 showed no benefit over placebo
- Mechanism of action in humans remains speculative
Some practitioners watch AOD-9604 because it is cheap and easy to obtain. But the gap between animal data and human outcomes is wide. A compound that works in a rat adipocyte does not automatically work in a human with insulin resistance and a high-calorie diet.
How practitioners compare the two
In clinical conversations, semaglutide and AOD-9604 are rarely presented as direct competitors. Semaglutide is a prescription drug with a defined titration schedule and known side effects. AOD-9604 is a peptide fragment with no approved human use and no reliable dosing guidance. A practitioner who prescribes semaglutide is working within standard care. A practitioner who recommends AOD-9604 is operating outside the evidence base.
That does not mean AOD-9604 has no audience. Some patients who cannot tolerate GLP-1 side effects look for alternatives. Others want something that targets fat directly rather than suppressing appetite. The problem is that AOD-9604 has not been shown to do that in humans. A 2022 review in Peptides noted that most peptide-based fat loss agents fail in human trials because the biology is more complex than a single receptor interaction.
Semaglutide reduces energy intake. AOD-9604, if it works, would increase energy expenditure. Those are different levers, and the evidence for the second lever is much weaker.
For stubborn fat specifically, the honest answer is that no drug selectively removes fat from a particular area. Semaglutide reduces total fat mass, and some of that will come from stubborn areas, but not preferentially. AOD-9604 has not been shown to do even that. The idea of a "spot reduction" peptide is not supported by human data.
Supply, pricing, and regulatory pressure
Semaglutide pricing has been a persistent issue. The branded product costs over $1,000 per month in the US without insurance. Compounded versions, made by pharmacies during shortages, have filled a gap but face legal challenges from the manufacturer. A 2023 report in Reuters documented multiple lawsuits against compounding pharmacies selling semaglutide. The FDA has also warned about dosing errors with compounded GLP-1 products.
AOD-9604 sits in a different regulatory space. It is not approved, so there is no legitimate supply chain. Vendors sell vials labeled "for research purposes only." Prices are low, often under $50 per vial, but purity and sterility are unverified. A 2021 study in Analytical Chemistry found that many online peptide vendors sell products with incorrect amino acid sequences or no active ingredient at all.
- Branded semaglutide: $900-$1,300 per month
- Compounded semaglutide: $200-$400 per month, legal gray area
- AOD-9604: $30-$80 per vial, no quality control
- Insurance coverage for semaglutide is improving but inconsistent
Practitioners who prescribe semaglutide must navigate prior authorizations, supply shortages, and patient cost concerns. Those who discuss AOD-9604 face a different problem: there is no reliable product to recommend, and no dosing protocol backed by human data.
What the next few years look like
Semaglutide will likely remain the dominant GLP-1 for weight loss until oral versions and next-generation agents like tirzepatide take more market share. Tirzepatide, a dual GIP/GLP-1 agonist, showed even greater weight loss in trials, with average reductions of 20% or more. A 2023 trial in The New England Journal of Medicine reported 21.1% mean weight loss at 72 weeks. That shifts the conversation from semaglutide versus AOD-9604 to semaglutide versus tirzepatide versus whatever comes next.
AOD-9604 is unlikely to gain regulatory approval. The original developer abandoned it, and no large company has picked it up. It will continue to circulate in the peptide gray market, often bundled with other unapproved compounds like tesamorelin, CJC-1295, or hexarelin. Some practitioners watch these combinations, but the evidence for any of them in human fat loss is thin.
The likely trajectory is a widening gap. Semaglutide and its successors will become more accessible as prices fall and oral formulations launch. AOD-9604 will remain a research chemical with a loyal but small following. For patients asking about stubborn fat, the answer will stay the same: total fat loss is the only proven lever, and semaglutide pulls that lever harder than any peptide fragment.
Outcomes described in studies cited here cannot be assumed to generalise to individual users.
Common questions
Can AOD-9604 be used with semaglutide?
There is no human data on combining AOD-9604 with semaglutide. Semaglutide reduces appetite and slows gastric emptying; AOD-9604, if it works, would act on fat cells. The two mechanisms do not obviously conflict, but the absence of safety data is a problem. A practitioner would be cautious about recommending an unapproved peptide alongside a prescription GLP-1 agonist. The risk of unknown interactions, plus the quality issues with gray market AOD-9604, makes this combination speculative at best.
Does semaglutide target belly fat specifically?
No. Semaglutide reduces total body fat, and belly fat loss is proportional to overall loss. Some people lose visceral fat faster than subcutaneous fat, but that is driven by individual biology, not the drug. A 2022 analysis of STEP trial data showed that visceral fat decreased by roughly 30% in participants who lost 15% of body weight, which is consistent with what would be expected from any substantial weight loss. There is no evidence that semaglutide preferentially targets abdominal fat.
Is AOD-9604 legal to buy?
In the United States, AOD-9604 is not an FDA-approved drug, so it cannot be legally sold for human consumption. Vendors label it as a research chemical, which places the product in a legal gray area. The FDA has issued warning letters to companies selling AOD-9604 as a dietary supplement or weight loss aid. Buyers assume the risk of impure product, incorrect dosing, and legal exposure. Practitioners generally do not recommend it for these reasons.
How much weight can you lose with semaglutide?
In clinical trials, semaglutide 2.4 mg weekly produced average weight loss of 14-17% from baseline over 68 weeks. Some participants lost more than 20%, while others lost less than 5%. The response varies with adherence, diet, and baseline metabolic health. Real-world data suggest slightly lower averages, around 10-12%, because patients are less consistent with dosing and lifestyle changes than trial participants. The weight loss is primarily fat mass, with some lean mass loss as well.